Regulatable membrane-bound IL-15 engineered TIL cell therapy for immune checkpoint inhibitor-resistant advanced melanoma: pooled analysis of phase 1 and 1/2 trials

Rodabe N. Amaria, Jason A. Chesney, Allison S. Betof, Gino K. In, Alexander N. Shoushtari, Tirrell T. Johnson, Omid Hamid, Yazan Samhouri, Michael A. Davies, Hussein A. Tawbi, Isabella C. Glitza Oliva, Bulent Arman Aksoy, Amanda M. Kelly, Raina Duan, Prakash Prabhakar, Giridharan Ramsingh, Madan Jagasia, Parameswaran Hari

Open source

DOI: 10.1038/s41591-026-04743-6
Published: 2026-11-03
Container: Nature Medicine
Publisher: Springer Science and Business Media LLC
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41591-026-04743-6,
  title = {Regulatable membrane-bound IL-15 engineered TIL cell therapy for immune checkpoint inhibitor-resistant advanced melanoma: pooled analysis of phase 1 and 1/2 trials},
  author = {Rodabe N. Amaria and Jason A. Chesney and Allison S. Betof and Gino K. In and Alexander N. Shoushtari and Tirrell T. Johnson and Omid Hamid and Yazan Samhouri and Michael A. Davies and Hussein A. Tawbi and Isabella C. Glitza Oliva and Bulent Arman Aksoy and Amanda M. Kelly and Raina Duan and Prakash Prabhakar and Giridharan Ramsingh and Madan Jagasia and Parameswaran Hari},
  year = {2026},
  journal = {Nature Medicine},
  doi = {10.1038/s41591-026-04743-6},
  url = {https://doi.org/10.1038/s41591-026-04743-6}
}

RIS

TY  - JOUR
TI  - Regulatable membrane-bound IL-15 engineered TIL cell therapy for immune checkpoint inhibitor-resistant advanced melanoma: pooled analysis of phase 1 and 1/2 trials
AU  - Rodabe N. Amaria
AU  - Jason A. Chesney
AU  - Allison S. Betof
AU  - Gino K. In
AU  - Alexander N. Shoushtari
AU  - Tirrell T. Johnson
AU  - Omid Hamid
AU  - Yazan Samhouri
AU  - Michael A. Davies
AU  - Hussein A. Tawbi
AU  - Isabella C. Glitza Oliva
AU  - Bulent Arman Aksoy
AU  - Amanda M. Kelly
AU  - Raina Duan
AU  - Prakash Prabhakar
AU  - Giridharan Ramsingh
AU  - Madan Jagasia
AU  - Parameswaran Hari
PY  - 2026
JO  - Nature Medicine
DO  - 10.1038/s41591-026-04743-6
UR  - https://doi.org/10.1038/s41591-026-04743-6
ER  -

APA

Amaria, R. N., Chesney, J. A., Betof, A. S., In, G. K., Shoushtari, A. N., Johnson, T. T., Hamid, O., Samhouri, Y., Davies, M. A., Tawbi, H. A., Oliva, I. C. G., Aksoy, B. A., Kelly, A. M., Duan, R., Prabhakar, P., Ramsingh, G., Jagasia, M., & Hari, P. (2026). Regulatable membrane-bound IL-15 engineered TIL cell therapy for immune checkpoint inhibitor-resistant advanced melanoma: pooled analysis of phase 1 and 1/2 trials. Nature Medicine. https://doi.org/10.1038/s41591-026-04743-6

Source records

crossref · retrieved 2026-11-06T14:26:38.709Z